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Abstract: Background: Despite being recognised that nutritional intervention is essential, nutritional
support is not widely accessible to all patients. Given the incidence of nutritional risk and nutrition
wasting, and because cachexia management remains a challenge in clinical practice, a multidisciplinary
approach with targeted nutrition is vital to improve the quality of care in oncology. Methods:
A literature search in PubMed and Cochrane Library was performed from inception until 26 March.
The search consisted of terms on: cancer, nutrition, nutritional therapy, malnutrition, cachexia,
sarcopenia, survival, nutrients and guidelines. Key words were linked using “OR” as a Boolean
function and the results of the four components were combined by utilizing the “AND” Boolean
function. Guidelines, clinical trials and observational studies written in English, were selected.
Seminal papers were referenced in this article as appropriate. Relevant articles are discussed in this
article. Results: Recent literature supports integration of nutrition screening/assessment in cancer
care. Body composition assessment is suggested to be determinant for interventions, treatments
and outcomes. Nutritional intervention is mandatory as adjuvant to any treatment, as it improves
nutrition parameters, body composition, symptoms, quality of life and ultimately survival. Nutrition
counselling is the first choice, with/without oral nutritional supplements (ONS). Criteria for escalating
nutrition measures include: (1) 50% of intake vs. requirements for more than 1–2 weeks; (2) if it
is anticipated that undernourished patients will not eat and/or absorb nutrients for a long period;
(3) if the tumour itself impairs oral intake. N-3 fatty acids are promising nutrients, yet clinically
they lack trials with homogeneous populations to clarify the identified clinical benefits. Insufficient
protein intake is a key feature in cancer; recent guidelines suggest a higher range of protein because
of the likely beneficial effects for treatment tolerance and efficacy. Amino acids for counteracting
muscle wasting need further research. Vitamins/minerals are recommended in doses close to the
recommended dietary allowances and avoid higher doses. Vitamin D deficiency might be relevant
in cancer and has been suggested to be needed to optimise protein supplements effectiveness.
Conclusions: A proactive assessment of the clinical alterations that occur in cancer is essential for
selecting the adequate nutritional intervention with the best possible impact on nutritional status,
body composition, treatment efficacy and ultimately reducing complications and improving survival
and quality of life.
Keywords: cancer; nutrition; nutritional therapy; nutritional support; malnutrition; cachexia;
sarcopenia; survival
1. Introduction
Cancer is a complex disease that results from multiple interactions between genes and the
environment, and is regarded as one of the current leading causes of mortality worldwide [1,2].
Metabolic and nutritional alterations can influence survival and recovery of cancer patients:
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malnutrition, sarcopenia and cachexia [3,4]. Malnutrition ensues from an inflammatory state that
promotes anorexia and consequently, weight loss. It is highly prevalent in cancer patients [5] as 15 to
40% of patients report weight loss at diagnosis [6]. It is estimated that 40 to 80% of all cancer patients will
be malnourished during the course of the disease. Furthermore, malnutrition can influence treatment
outcomes, delay wound healing, worsen muscle function and increase the risk of post-operative
complications. It can also impair tolerance and response to antineoplastic treatments, which can in
turn lead to extended hospital stay, increase the risk for treatment interruptions, and possible reduced
survival [7,8]. Sarcopenia is characterised by a decrease in lean body mass with an impact both on
strength and physical function that may decrease the quality of life [9]. As cancer-related weight loss
in obese patients cannot be identified by a low body mass index (BMI), sarcopenic obesity, defined
as low lean body mass in obese patients, is frequently overlooked [10]. In these patients, changes in
body composition result in an increased metabolic risk, and it seems to be a significant predictor of
treatment related adverse events [11,12]. Cancer cachexia is a complex multifactorial syndrome that
results from a combination of metabolic alterations, systemic inflammation and decreased appetite.
It is characterised by an involuntary sustained weight loss and loss of skeletal muscle mass, with or
without loss of fat mass that are irreversible by conventional nutritional support [13].
In addition to the disease, antineoplastic treatments and/or surgery have a significant impact
on patients’ nutritional status [14–16]. During chemotherapy (CT), more than 50% of patients
experience dysgeusia, nausea, vomiting and mucositis, and radiotherapy (RT) related complications
are also common. It is also established that poor nutritional status increases surgical morbidity and
post-surgical complications [17]. Nutritional intervention in cancer patients aim to identify, prevent and
treat malnutrition through nutritional counselling with or without oral nutritional supplements (ONS)
or via artificial nutrition, i.e., enteral or parenteral nutrition [18–20], as well as to address metabolic
and nutritional alterations that influence patients’ recovery and survival [19,20]. Despite the fact that
nutritional intervention is a key component, nutritional support is not widely accessible to all patients
at nutritional risk [21–23]. Additionally, given the incidence of nutritional risk in cancer and the fact that
the management of cachexia remains a challenge in clinical practice [24], a multidisciplinary approach
is vital to define efficient strategies that can improve quality of care in cancer patients. According
to the reviewed data and guidelines, nutritional intervention should be central and adjuvant to any
treatment and should be included in the multidisciplinary approach mandatory in oncology. This will
allow for more adequate and efficient results in these patients. Multidisciplinary follow-up, with early
and regular nutritional intervention, is of major importance in oncology, thus being a key factor for
successful treatment and recovery. The present article aims to provide insights and an overview of the
most recent literature regarding key nutritional aspects in cancer patients.
Based on this framework, a literature search in PubMed and Cochrane Library was performed
from inception until 26 March. The search consisted of terms: cancer, nutrition, nutritional therapy,
malnutrition, cachexia, sarcopenia, survival, nutrients, guidelines. Key words were linked using “OR”
as a Boolean function and the results of the four components were combined by utilizing the “AND”
Boolean function. Guidelines, clinical trials and observational studies written in English, were selected.
Seminal papers in the area, even if dated outside the search timeline, were referenced in this article
as appropriate.
2. Results
2.1. Nutritional Screening and Assessment
Screening for nutritional risk as early as possible allows for the identification of patients at
risk of becoming malnourished [25]. Screening should be done as early as possible, and recent
literature suggests that it should be done at diagnosis or at hospital admission; screening should be
repeated in the course of treatment for referral for evaluation if needed [19,21,23,25–27]. Evidence
supports the integration of malnutrition screening in cancer patients care. The adequate tool for
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screening undernutrition should be brief and easy to fill, inexpensive, highly sensitive and have
good specificity [25]. MUST (Malnutrition Universal Screening Tool) and NRS-2002 (Nutritional Risk
Screening-2002) are considered suitable [28–30]; the MNA (Mini Nutritional Assessment) is a suitable
tool for nutritional assessment in the senior population [19,23].
When nutritional risk is present, screening should be followed by comprehensive nutritional
assessment to better determine the course of nutritional intervention. It seems there is no consensus on
the best method to perform this assessment, but SGA (Subjective Global Assessment) and PG-SGA
(Patient Generated-Subjective Global Assessment) have been validated for nutritional assessment of
adult oncology patients [25,26,31].
When used isolated, weight loss is ineffective to detect malnutrition, as it has low sensitivity
for metabolic changes that occur in cancer patients. Yet, its early and regular assessment, combined
with the evaluation of nutritional intake, BMI and inflammatory status is a standard clinical
recommendation [19,26]. As for BMI, it has low sensitivity to detect changes in the nutritional
status, especially in obese patients, thus it should only be used combined with other assessment
tools [26,32].
Body composition provides valuable information in the management of cancer patients, as imaging
methods detect loss of muscle mass as well as fatty muscle infiltration [2]. In cancer patients at risk for
malnutrition, sarcopenia and cachexia, muscle mass should be assessed [19,21]. Methods available
are dual X-ray absorptiometry (DEXA), computed tomography scans at the level of the 3rd vertebra
or bioimpedance analysis (BIA). Additionally, it has been recommended that nutritional assessment
should be performed for the stages of cancer cachexia, as nutritional intervention is most effective in
the stages of precachexia and cachexia [13].
2.2. Nutritional Intervention
In order to tackle nutritional deterioration, gathering objective data on nutritional status and its
evolution throughout the disease course is of prime concern. Different cancer types or locations display
different nutritional patterns that require tailored nutritional therapy. Nutritional deterioration is a
multifactorial end-result determined by cancer-related and nutrition- and/or metabolic-related factors.
Proper nutrition can alleviate symptom burden, improve health across the cancer continuum, support
cancer survivorship [33–36] and is a hallmark of successful cancer treatment.
Nutritional interventions will vary according to patients’ medical history, type and stage of cancer,
as well as to the response to treatment. If the patient can eat and has a functional gastrointestinal tract,
nutritional counselling, with or without ONS should be the elected intervention to address altered
nutritional demands due to treatment or disease [19,21,26]. ONS may be necessary, as a means to
compensate for lower food intake and to try to prevent nutritional deterioration during the course of
treatments. Monitoring compliance with the selected nutritional intervention is essential.
2.2.1. Individualised Nutritional Counselling
In clinical practice, oral nutrition is always the priority. Oral nutrition is the preferred route of
feeding as it is a significant part of the patient’s daily routine and does contribute substantially to the
patients’ autonomy [19]. It represents a privileged time to spend with family and friends, avoiding
the tendency for isolation. The acknowledgement that the prescribed diet is individualized, adapted
and adequate to individual needs, empowers the patient with a feeling of control, thus it is also a
highly effective approach for psychological modulation. All these factors may potentially contribute to
improve the patients’ quality of life, and may modulate acute and late treatment morbidity. The referral
for a nutrition professional responsible for the individualised dietary counselling should always be
based on decision-making plans (Figure 1).
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by the family and caregivers, as essential to maintain the daily activity, energy, functional capacity 
and to overcome treatments more successfully. Notably, nutritional wasting is common regardless 
of the cancer stage (curative, adjuvant, to palliative) and is an independent predictor of poor physical 
function, lower quality of life, surgical complications, and reduced survival [3,10,13,37]. Cancer 
wasting is characterised by muscle mass deterioration that occurs in more than 50% of newly 
diagnosed cancer patients, in comparison with 15% prevalence in healthy individuals of similar age 
[38]. Since both muscle mass and adipose tissue play a role in oncological outcomes, strategies to 
optimize body composition are an important part of successful cancer therapy. Hence, a major goal 
of nutrition intervention is to favourably influence body composition, with the potential to improve 
cancer therapy outcomes, morbidities and ultimately, prognosis. 
To be effective, individualised counselling has to be based on a thorough assessment of various 
nutritional and clinical parameters: nutritional status and dietary intake, usual dietary pattern, 
intolerances or food aversions, patients’ psychological status, autonomy, cooperation, need for help 
or support of others in the act of eating. A thorough symptom assessment is also mandatory (Table 1). 
Table 1. Common causes for a poor nutrient intake in cancer patients. 
• Deterioration in taste, smell and appetite, as a consequence of the tumour and/or therapy  
• Altered food preferences/food avoidance/food aversion  
• Eating problems (teeth, chewing)  
• Dysphagia, odynophagia or partial/total gastrointestinal obstruction  
• Early satiety, nausea and vomiting  
• Soreness, xerostomia, sticky saliva, painful throat, trismus  
• Oral lesions and oesophagitis  
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Figure 1. Evidence based decision making plan.
As clinicians we have to recognise the dimensions that are determinant for the patients. Indeed,
the diet is the only factor that the patient feels he/she can control during the whole course of treatments
and interventions. Also, an adequate food intake is recognised by the patient as well as by the
family and caregivers, as essential to maintain the daily activity, energy, functional capacity and to
overcome treatments more successfully. Notably, nutritional wasting is common regardless of the
cancer stage (curative, adjuvant, to palliative) and is an independent predictor of poor physical function,
lower quality of life, surgical complications, and reduced survival [3,10,13,37]. Cancer wasting is
characterised by muscle mass deterioration that occurs in more than 50% of newly diagnosed cancer
patients, in comparison with 15% prevalence in healthy individuals of similar age [38]. Since both
muscle mass and adipose tissue play a role in oncological outcomes, strategies to optimize body
composition are an important part of successful cancer therapy. Hence, a major goal of nutrition
intervention is to favourably influence body composition, with the potential to improve cancer therapy
outcomes, morbidities and ultimately, prognosis.
To be effective, individualised counselling has to be based on a thorough assessment of various
nutritional and clinical parameters: nutritional status and dietary intake, usual dietary pattern,
intolerances or food aversions, patients’ psychological status, autonomy, cooperation, need for help or
support of others in the act of eating. A thorough symptom assessment is also mandatory (Table 1).
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Table 1. Common causes for a poor nutrient intake in cancer patients.
• Deterioration in taste, smell and appetite, as a consequence of the tumour and/or therapy
• Altered food preferences/food avoidance/food aversion
• Eating problems (teeth, chewing)
• Dysphagia, odynophagia or partial/total gastrointestinal obstruction
• Early satiety, nausea and vomiting
• Soreness, xerostomia, sticky saliva, painful throat, trismus
• Oral lesions and oesophagitis
• Radiotherapy/chemotherapy induced mucositis
• Acute or chronic radiation enteritis during and after radiotherapy
• Depression, anxiety
• Pain
Individualised nutritional counselling taking into consideration patients’ clinical condition and
symptoms, was the most effective nutrition intervention, assuring a sustained and adequate diet,
which was able to overcome the predictable deterioration subsequent to RT [35,36,39–42]. Positive
effects were experienced in the long term with a possible impact of patients’ prognosis [43] as recently
showed in a randomized trial, the preliminary results of which were presented in the ESPEN Congress
in 2018. Another randomised trial of nutritional therapy showed that intervention had an impact
in maintaining patients’ nutritional status and function [39]. In this study, individualised intensive
nutrition counselling was compared with individualised on-demand nutrition counselling by a
dietician prior to and during oncologic treatment. On-demand nutrition counselling requested by
physician/nurse referral, seemed not inferior to intensive counselling; thus, these results do emphasise
the importance of establishing multimodal nutrition teams to effectively and timely screen and orient
patients for adequate nutrition [39]. Several guidelines to date do include nutritional counselling as
their standard of care for malnourished patients or at risk of malnutrition [19–21,23,26,27] or during
anti-neoplastic treatments in head-neck (HNC), oesophageal and colorectal cancers as these patients
are in particular risk of malnutrition due to tumour location and irradiated area [14].
If/when oral nutrition is inadequate/insufficient, artificial nutrition should be considered [19–21,
23,26,27]. Criteria for the escalation in nutritional measures are: (1) inadequate food intake (<50% of
requirements) is anticipated for more than 10 days due to surgery or chemotherapy (CT)/radiotherapy
(RT); (2) if food intake is less than 50% of the requirements for more than one to two weeks; (3) if it is
anticipated that undernourished patients will not be able to eat and/or absorb the adequate amount
of nutrients for a long period time, due to antineoplastic treatments; (4) if the tumour mass itself
impairs oral intake and food progression through the upper GI tract. The decision between enteral
nutrition (EN) and parenteral nutrition (PN) must take into account the site of the tumour, its extent,
complications, treatment plan and intent, prognosis, patients’ overall physical status and the duration
of the nutritional support [19–21,23,26,27,44].
2.2.2. Artificial Nutrition
If the intestinal functions are preserved, EN should be preferred in order to maintain gut
integrity and reduce bacterial translocation [45], as well as to reduce infectious complications [19–
21,23,26]. A standard polymeric feeding formula should be preferred. EN is recommended in
undernourished or at-risk patients during CT if undernutrition is present or if inadequate food intake
is present or anticipated [19,22,23,27,46]. Systematic artificial nutrition during CT treatment is not
recommended [19–21,23,26]. In radiation-induced severe mucositis or in obstructive tumours of the
head-neck or thorax, either PEG or nasogastric tube are recommended [19,20]. EN is contraindicated
in: intestinal obstruction or ileus, severe shock, intestinal ischaemia, high output fistula, severe
intestinal haemorrhage, intestinal insufficiency due to radiation enteritis, short bowel syndrome,
peritoneal carcinomatosis chylothorax [19,21,23,26]. In these situations, or whenever EN is insufficient,
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a combination of EN and PN or PN alone should be considered [19,21,23,26]. As for PN, it should
be initiated early [19,21,23,26] whenever indicated. PN is the first option of nutritional support in
cases of intestinal failure; whenever macro and micronutrient’ requirements can only be fulfilled via
the parenteral route, long term artificial nutrition as home parenteral nutrition (HPN) is standard
recommendation [19,44,47,48].
As for the macronutrients in PN, amino acids (AA) requirement of cancer patients relies on:
negative balance between whole body protein synthesis and breakdown, doses of AA closer to 2 g/kg/day
may be required to control catabolism and stimulate synthesis vs. 0.8 g/kg/day as recommended
for healthy subjects [49], and for older subjects and chronic disease, most recent clinical guidelines
recommend >1.0 g/kg/day of protein. Hence, to support protein balance, up to 1.5 g/kg/day or more of
protein is the consensual recommendation. In the nutritive PN admixtures, essential AA should be
present in approximately 50% of AA and branched chain AA should account for the remainder 50%
of total AA [50]. In what concerns fat as an energy substrate, the most consensual regimens have fat
accounting for ≈50% of non-protein calories [51,52].
Recently, PN as a supplemental route of nutrient administration (SHPN) emerged as a possible
resource to optimise nutrient delivery. Prospective studies [53–57] on SHPN suggest a possible
benefit in energy balance, increased body fat, greater maximum exercise capacity and QoL. A recent
randomised trial showed that SHPN may prevent loss of MM in patients with incurable gastrointestinal
cancer [57]. Hence, there is yet insufficient evidence to recommend SHPN in cancer patients to improve
QoL and nutrition parameters. Additionally, practice of HPN differs between countries; most do not
consider the use of PN if there is a functional gastrointestinal tract, while others may consider its use if
it is according to the will of the patient [58–60].
Refeeding syndrome can occur when severe shifts in fluids and electrolytes happen in severely
malnourished patients receiving EN or PN, and it may cause hypophosphatemia, hypokalaemia,
hypomagnesaemia, thiamine deficiency, changes in sodium, glucose and fluid balance and also in
protein and lipid metabolism [19,21]. Its prevention is recommended when BMI < 16 kg/m2 or in the
presence of unintentional weight loss >15% within the last three to six months or whenever there
is little or no nutritional intake for more than 10 days or if there are decreased levels of potassium,
phosphate or magnesium prior to feeding. If a severe decrease in food intake occurs for at least five
days, it is recommended a gradual increase in nutrition over several days, and no more than 50% of
the calculated energy requirements should be supplied during the first two days of feeding [19,25].
The identified fluid and electrolytes imbalances should be corrected, and the circulatory volume, fluid
balance, heart rate and rhythm, as well as clinical status, should be monitored closely. Attention to the
refeeding syndrome risk is currently contemplated in guidelines for cancer management [19–23,26,27].
2.2.3. Surgery
In order to minimise the metabolic stress response and catabolism associated with surgery in
undernourished patients, the enhanced recovery after surgery program (ERAS) is recommended for
all cancer patients undergoing curative or palliative surgery [18,22,61]. Within ERAS protocol the
following principles should be followed: Screening for malnutrition and give additional nutritional
support if necessary [18,22]; avoid preoperative fasting; preoperative carbohydrate treatment should
be considered as well as the reestablishment of oral feeding on the first postoperative day; and early
mobilisation [18,22]. To avoid preoperative fasting, patients with no risk of aspiration, are allowed to
eat solid food until six hours and drink clear fluids until two hours before anaesthesia [18].
In oncologic surgical patients, with moderate to severe nutritional risk, nutritional support is
recommended before and after surgery [18,25]. If severe malnutrition is present, delaying surgery
may be necessary [18,25]. When submitted to major surgery, nutritional support should be provided
routinely, with particular attention to elderly sarcopenic patients.
Besides the ERAS protocol, an early start of nutritional supplementation can significantly diminish
the degree of weight loss and incidence of complications [22,25]. If it is anticipated that after surgery,
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the patient will be unable to eat for more than seven days, it is advised to start nutrition therapy
even in well-nourished patients [18,22,25]. After surgery, oral nutrition should also be preferred to
EN and the latter should be preferred to PN. If oral intake is possible, it should start after surgery
without interruption, after assessing individual tolerance. If oral nutrition is not possible, EN should
be initiated within 24 h, preferring standard polymeric enteral formulae if adequate [25].
2.2.4. Radiotherapy and Chemotherapy
Oral mucositis, dysphagia and diarrhoea are common complications of RT and/or CT
treatments [12–22]. During RT, nutritional counselling is also recommended, especially in HNC,
thorax and gastrointestinal (GI) tract cancers [12–23]. When deemed necessary, ONS should be
provided [62], and when severe mucositis is present, artificial nutrition should be considered [23].
When dietary counselling and ONS are insufficient to reduce weight loss or if in the presence of
severe mucositis or obstructive tumours of the head or neck or thorax, artificial nutrition should be
considered [19,20,23]. In patients treated with RT or chemoradiotherapy, PN is not recommended [19],
and it should only be considered when adequate nutrition cannot be assured with oral or EN [19].
2.3. Specific Nutrients
Nutritional strategies that potentially allow better management of cancer have been widely
investigated, but few have reached conclusive results.
2.3.1. Protein
Many patients with cancer do not meet the recommended intake (1.2–1.5 g/kg/day), and not
even the one for healthy individuals (0.8 g/kg/day) [63]. Limited protein intake ensues mainly from
nutrition impact symptoms that affect dietary intake [64]. Recent guidelines do suggest a higher range
of protein intake (1.2–1.5 g/kg/day), because of the positive results of higher protein intake in protein
balancing and in maintaining muscle mass. Of additional interest is a recent study showing an inverse
association between red meat consumption and seven-year mortality among 992 individuals with
stage III colon cancer [65], suggesting that higher protein intake may actually be beneficial in cancer.
Interventions with amino acids have been tested in cancer, aiming to optimise nutritional status
and counteract muscle mass wasting. They include supplementation with branched chain amino acids
(leucine, isoleucine and valine) [63], β-hydroxy β-methyl butyrate, carnitine and creatine. Yet further
research is needed to clarify potential benefits.
As for glutamine, its supplementation in cases of oral mucositis or to prevent/treat diarrhoea
during pelvic RT, is not recommended [19,22,26]. As for its use when PN is required for patients
undergoing haematopoietic stem cell transplant, guidelines are not identical: there is a fair graded
recommendation for eventual use of 0.2–0.5 g/kg/day [26], and the indication that there is not enough
evidence to recommend for or against glutamine to reduce anticancer therapy side effects, especially in
high dose protocols [19]. In what concerns its potential to improve muscle mass, there is not enough
data to support it.
2.3.2. Eicosapentaenoic Acid and Fish Oil
Eicosapentaenoic acid (EPA) has been identified as a promising nutrient with appointed clinical
benefits. Several mechanisms have been proposed to explain the potential benefits of EPA on the
body composition: inhibition of catabolic stimuli by modulating the production of pro-inflammatory
cytokines and enhancing insulin sensitivity that induces protein synthesis. Intervention studies showed
that EPA may attenuate deterioration of nutritional status and may aid in improving calorie and
protein intake. Recent systematic reviews found that EPA can reduce inflammation and has a potential
to modulate the nutritional status/body composition [66,67]. Furthermore, some studies suggest that
n−3 fatty acids inhibit proliferation of cancer cells [68] and might decrease CT toxicity [69]. Given
the large number of studies reporting a positive impact of n−3 fatty acids on the muscle mass, it is
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likely that this would be a practical and effective intervention for preventing loss of muscle without
significant side effects [19]. It is noteworthy that the strength of recommendation somewhat differs for
the use of n−3 fatty acids supplementation in weight losing cancer patients not responding to standard
nutritional therapy. This recommendation has been rated as strong [26] and weak [19]. Nevertheless,
both guidelines are inclined to consider supplementation with long chain fatty acids and fish oil to
decrease systemic inflammation and improve appetite, food intake and body weight.
Trials with homogeneous patient populations regarding cancer type, stage, anti-neoplastic
regimens, supplement dosage and modality of administration are needed to clarify clinical benefits.
Indeed, it is noteworthy that in view of the modest survival benefits of CT/RT in some cancers,
important issues for physicians are to optimize well-being, quality of life via nutritional status and
adequate body composition [70].
2.3.3. Micronutrients
Because of the adverse effects of therapy and restricted diet of many patients, the American
Institute for Cancer Research [71], American Cancer Society [72] and the European Society for Clinical
Nutrition and Metabolism—ESPEN [19] support the use of a multivitamin-multimineral supplement
in doses close to the recommended dietary allowance. High doses of vitamins and minerals are
discouraged in the absence of specific deficiencies [19,20]. Vitamin D deficiency might be relevant in
cancer [19]; also, an association has been reported between low vitamin D and muscle wasting. As a
consequence, vitamin D may be needed to optimise protein supplements effectiveness. In light of the
recent literature, vitamin D supplementation with 600–800 international units (RDA) in cancer patients
can be beneficial in the context of preventing muscle wasting, but further research is needed.
3. Discussion
In cancer, deterioration and muscle wasting result from the combination of reduced nutrient
absorption, alterations in appetite, taste and/or dietary intake, hormone-induced metabolic changes
and cancer-related immune activation with cytokine release. Regardless of the underlying mechanisms,
cancer-related weight loss is a multidimensional manifestation that worsens patients’ well-being,
tolerance to antineoplastic therapies and prognosis. Clinically speaking, weight loss is frequent in
cancer patients, and depending on the location of the tumour, it is present in 15 to 40% of cancer patients
at diagnosis. Weight loss is frequently the first sign of the nutritional alterations that occur in the
course of the disease and is associated with poor prognosis, reduced quality of life and morbidity [62].
Cancer cachexia can be defined as ‘a multi-factorial syndrome defined by an ongoing loss of skeletal muscle
mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support. It
leads to progressive functional impairment. Its pathophysiology is characterized by a negative protein and
energy balance driven by a variable combination of reduced food intake and abnormal metabolism’. The agreed
diagnostic criterion for cachexia was weight loss >5%, or weight loss >2% in individuals already
showing depletion of body weight (BMI < 20 kg/m2) or of skeletal muscle (sarcopenia). Assessment for
classification and clinical management should also include the following domains: ‘anorexia/reduced
food intake, catabolic drive, muscle mass and strength, functional and psychosocial impairment’ [13].
The main nutritional problem in cancer is wasting of muscle mass, acknowledged to be a
predictor of lower quality of life, impaired functionality, surgical complications and shortened
survival [10,63,73,74]. Of note that sarcopenia occurs independently of loss of weight or of fat mass.
Thus, a clinically relevant phenotype that also emerged in cancer is characterised by sarcopenia with
excessive fat mass. Additionally, to the previous studies demonstrating the major impact of muscle
mass depletion on survival and treatment toxicity [73,74], a recent study in a cohort of head-neck
cancer patients, showed that patients with cachexia had a worse disease-free survival compared with
non-cachectic patients [12,39].
Bearing this in mind, the clinical efforts and priority given to improve treatment outcomes,
will logically have to include nutritional intervention and adequacy of body composition. The search
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for an effective nutritional intervention that improves body composition (preservation of muscle mass
and muscle quality) is of utmost importance for clinicians and patients, given the implications for
prognosis. Early detection of malnutrition and cachexia should be part of a multimodal approach to
improve both patient-centred and oncology outcomes [47].
4. Conclusions
In the present article, the most recent guidelines for the management of cancer patients, as well
as original studies in nutrition and cancer, were included. Nutrition is a central factor in oncology,
influencing the development of the disease, tumour inherent symptoms, response to, and recovery
after anti-neoplastic treatment(s), thus having a strong impact on the quality of life and prognosis
of the disease. A main nutritional feature is wasting of muscle mass, strongly associated with
decreased functional capacity, higher incidence of chemotherapy toxicity, increased hospitalization and
complication rate, as well as mortality. Nutritional risk screening and assessment in cancer patients
allows for the early detection of malnourished patients and also for a prompt nutritional intervention
aiming to prevent nutritional deterioration and muscle wasting. A proactive assessment of the clinical
alterations that occur during treatments and during the disease course, is essential for selecting the
adequate nutritional intervention, aiming for the best impact on patients’ outcomes. Early tailored
intervention has the potential to improve body composition and treatment’ efficacy, and as evidence
stands, it is an obligatory adjuvant intervention, with the likelihood of improving prognosis of the
disease itself.
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